Trevena, Inc. (NASDAQ:TRVN), a clinical stage biopharmaceutical company
focused on the discovery and development of G protein coupled receptor
(GPCR) biased ligands, today announced that Maxine Gowen, Ph.D., its
president and chief executive officer, will present at the 9th Annual
JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at
11:00 a.m. EDT at The Westin Grand Central in New York City.
To access a live audio webcast of the presentation, please visit the
"Investors" section at www.trevenainc.com.
The webcast will be archived for 30 days.
Trevena, Inc. is a clinical stage biopharmaceutical company that
discovers, develops and intends to commercialize therapeutics that use a
novel approach to target G protein coupled receptors, or GPCRs. Using
its proprietary product platform, Trevena has identified and advanced
three differentiated biased ligand product candidates into the clinic -
TRV027 to treat acute heart failure, TRV130 to treat moderate-to-severe
acute pain intravenously, and TRV734 to treat moderate-to-severe acute
and chronic pain orally. Trevena also is advancing additional product
candidates in its portfolio, including a preclinical program focused on
central nervous system indications.
[ Back To NFVZone's Homepage ]